OBJECTIVES: To evaluate the cost-effectiveness of IDeg U100 versus currently available basal insulins for the treatment of Type 1 (T1DM) and Type 2 (T2DM) diabetes mellitus in Belgium.

METHODS: A lifetime cost-effectiveness analysis of switching to IDeg U100 was conducted from a Belgian health-care payer perspective using the IQVIA CORE Diabetes Model. Clinical outcomes were sourced from a European, multicentre, retrospective, non-interventional chart review; the EUropean TREsiba AudiT (EU-TREAT). The most recently recorded HbA1c value, hypoglycaemia rate, insulin dose, and body weight were used as pre- (baseline) and post- switch outcomes (-3 to 0 and 6 ±3 months from switching to IDeg U100, respectively). Cost-effectiveness analyses were performed for the subgroups: T1DM patients on basal-bolus insulin (BB), T2DM patients on basal insulin only regimens (BOT) and T2DM patients on BB. The outcomes of interest were life years (LYs) gained and quality-adjusted life years (QALYs) gained. Utilities were obtained from a literature review. The robustness of the results was addressed via deterministic and probabilistic sensitivity analyses.

RESULTS: Switching to IDeg U100 from currently available basal insulins in Belgium was dominant in all base case analyses: T1DM patients each gained 0.14 LYs and 0.85 QALYs with a 5,414 EUR reduction in per patient lifetime costs of diabetes and complications, T2DM-BOT patients each gained 0.19 LYs and 0.14 QALYs with a 1,581 EUR reduction in lifetime costs of diabetes and complications; T2DM-BB patients each gained 0.13 LYs and 0.36 QALYs with a 2,167 EUR reduction in lifetime costs of diabetes and complications. The results of the sensitivity analyses confirmed the robustness of the dominant results.

CONCLUSIONS: Based on evidence from real-world clinical practice in the IQVIA CORE Diabetes Model, switching to IDeg U100 increases the life expectancy and quality-adjusted life expectancy of diabetes patients while reducing the total costs of diabetes in Belgium.